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Nanoparticles containing octreotide peptides
and gadolinium complexes for MRI
applications‡
Antonella Accardo,a Anna Morisco,a Eliana Gianolio,b Diego Tesauro,a
Gaetano Mangiapia,c Aurel Radulescu,d Astrid Brandte
and Giancarlo Morellia∗
New mixed nanoparticles were obtained by self-aggregation of two amphiplic monomers. The first monomer (C18)2L5-Oct
contains two C18 hydrophobic moieties bound to the N-terminus of the cyclic peptide octreotide, and spaced from the
bioactive peptide by five units of dioxoethylene linkers. The second monomer, (C18)2DTPAGlu, (C18)2DTPA or (C18)2DOTA,
and the corresponding Gd(III) complexes, contains two C18 hydrophobic moieties bound through a lysine residue to different
polyamino-polycarboxy ligands: DTPAGlu, DTPA or DOTA. Mixed aggregates have been obtained and structurally characterized
by small angle neutron scattering (SANS) techniques and for their relaxometric behavior. According to a decrease of negative
charges in the surfactant head-group, a total or a partial micelle-to-vesicle transition is observed by passing from (C18)2DTPAGlu
to (C18)2DOTA. The thicknesses of the bilayers are substantially constant, around 50 Å, in the analyzed systems. Moreover, the
mixed aggregates, in which a small amount of amphiphilic octreotide monomer (C18)2L5-Oct (10% mol/mol) was inserted, do not
differ significantly from the respective self-assembled systems. Fluorescence emission of tryptophan residue at 340 nm indicates
low mobility of water molecules at the peptide surface. The proton relaxivity of mixed aggregates based on (C18)2DTPAGlu(Gd),
(C18)2DTPA(Gd) and (C18)2DOTA(Gd) resulted to be 17.6, 15.2 and 10.0 mM−1 s−1 (at 20 MHz and 298K), respectively. The
decrease in the relaxivity values can be ascribed to the increase in τM (81, 205 and 750 ns). The presence of amphiphilic
octreotide monomer exposed on mixed aggregate surface gives the entire nanoparticles a potential binding selectivity toward
somatostatin sstr2 receptor subtype, and these systems could act as MRI target-specific contrast agent. Copyright c© 2010
European Peptide Society and John Wiley & Sons, Ltd.
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Introduction
Regulatory peptides represent a group of different families of
molecules known to act on multiple targets in the human body
at extremely low concentrations. They control and modulate the
function of almost all key organs and metabolic processes, acting
on several targets such as the brain; the gastrointestinal tract;
the endocrine system; the kidneys; the lungs, and the immune,
vascular, and peripheral nervous systems. Their action ismediated
through specificmembrane receptors; almost all belonging to the
group of G protein-coupled receptors [1,2].
Several synthetic analogs or chemically stabilized derivatives
of these peptides are studied as therapeutic agents in several
pathologies. The most successful example is the somatostatin
peptide: a cyclic 8-aa peptide (octreotide) (Sandostatin , Novartis,
Basel, Switzerland) [3]. This somatostatin analog is able to induce
endocytosis by binding to SSTR2 with high (IC50 = 2 nM) and
to SSTR 3 (IC50 = 376 nM) and SSTR 5 (IC50 = 299 nM) with
low affinity [4]. Because of the presence of unnatural D-amino
acid residues and the alcoholic C-terminus this peptide is highly
resistant to enzymatic degradation and is able to restore the β-
turn conformation required for interaction with the somatostatin
receptors [5]. In the light of these properties and of the non-
toxic side effects, octreotide is clearly a useful tool in cancer
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management; indeed more than 10 years ago it was introduced
in clinical practice to limit tumor growth [6]. Moreover, octreotide
has been used to deliver therapeutics or diagnostics on the
cellular target. In fact, by using the endocytosis mechanism [7]
in which, after octreotide binding, the receptor-ligand complex
is internalized, octreotide-drug conjugates containing the spindle
poison taxol [8] and peptide nucleic acid (PNA) sequences as
antisense therapeutics [9] have been developed. Furthermore,
for diagnostic use several octreotide derivatives modified at
the N-terminus with a bifunctional chelator suitable for labeling
radiometals such as 99mTc, 111In, and 67/68Ga have been designed,
synthesized, and used as in vivo contrast agents in nuclear
medicine techniques (SPECT and PET) [10–13].
The use of octreotide as target-selective delivery tool of
therapeuticordiagnosticnanoparticles is averychallengingobjec-
tive. Functionalized nanoparticles containing bioactive peptides
exposed on their external surface have been proposed as tar-
get selective drug carriers [14,15], as target selective contrast
agents in MRI [16–18], or as multimodal systems in which tar-
get selective therapeutic and imaging properties are combined
[19,20].
MRI contrast agents based on nanoparticles (micelles or
liposomes) have been developed with the aim of enhancing the
contrast efficacy. The labeling of gadolinium containing micelles
and liposomeswithbioactive peptides combine thehigh relaxivity
of the supramolecular aggregate and the target selectivity due to
the presence of the bioactive peptide.
Recently, we developed several supramolecular aggregates
derivatized with cholecystokinin (CCK8) [21–24] or bombesin
(7-14-bombesin) peptide fragments [25] which act as target selec-
tiveMRI contrast agents on cells overexpressing cholecystokininin
and GRP receptors, respectively. Moreover, we reported the re-
laxometric behavior of novel paramagnetic micelles obtained by
self-assembling of a monomer containing, in the same molecule,
threedifferent functions: (i) thechelatingagent (DTPAGluorDOTA)
able to coordinate gadolinium ion, (ii) the octreotide bioactive
peptide, and (iii) a hydrophobicmoiety with two 18-carbon atoms
alkyl chains [26]. The self-assembled DTPAGlu(Gd)octreotide mi-
celles present high relaxivity values, high stability upon dilution,
and efficient exposure of the bioactive octreotide peptide on
the micelle external surface. Anyway, due to the simultaneous
presence of an octreotide molecule and a gadolinium complex in
each amphiphilic monomer the Gd/peptide ratio in the final ag-
gregate is one and cannot be modified during nanoparticles
formation. Thus, by increasing the number of paramagnetic
gadolinium centers in the aggregate to enhance the relaxo-
metric properties of the contrast agent, the number of peptide
moieties on the aggregate surface also increases, providing pep-
tide–peptide interactions that could prevent peptide–receptor
binding.
In this paper we describe new mixed supramolecular adducts
obtained by self-aggregation of two monomers, one containing
the bioactive peptide and the other containing a chelating agent
able to complex the gadolinium ion. By using these monomers,
the gadolinium/octreotide ratio can be modulated as well with
the possibility of influencing the size and shape of the resulting
supramolecular aggregates; we describe nanoparticles containing
a large amount of gadolinium complexes on the hydrophilic
shell, while octreotide peptides are diluted on external aggregate
surface. The assembling properties and the relaxometric behavior
of the mixed aggregates are reported.
Materials and Methods
Protected Nα-Fmoc-amino acid derivatives, coupling reagents,
H-Thr(tBu)-ol-(2-chloro-trityl)-resin and Rink amide MBHA resin
were purchased from Calbiochem-Novabiochem (Lau¨felfingen,
Switzerland). The Fmoc-AdOO-OH was from Neosystem (Stras-
bourg,France).TheDTPAGlu(tBu)5 andN,N-dioctadecylsuccinamic
acid were prepared according to experimental procedures re-
ported in Ref. 27,28. (DOTA(tBu)3 and (DTPA(tBu)4 werepurchased
from Macrocycles (Dallas TX USA). All other chemicals were
commercially available by Sigma-Aldrich (Bucks, Switzerland) or
LabScan (Stillorgan, Dublin, Ireland) and were used as received
unless otherwise stated. All solutions were prepared by weight
with doubly distilled water. Solid phase peptide synthesis was
performed on a 433A Applied Biosystems automatic synthesizer
(Carlsbad, California). Analytical RP-HPLC runs were carried out on
anHPAgilent Series 1100 apparatus (Agilent, Santa Clara, CA, USA)
using a Phenomenex (Torrance, CA) C18 column, 4.6 × 250 mm
with a flow rate of 1.0 ml min−1. For all the RP-HPLC procedures
the system solvent used was 0.1% TFA in water (A) and 0.1% TFA
in CH3CN (B). The column was eluted with two linear gradients at
1.0 ml min−1 flow rate: (i) from5 to 70%B in 30 min followedby 70
to 95% B in 10 min and (ii) from 60 to 80% B over 10 min and from
80 to 95% B over 15 min. Preparative RP-HPLC were carried out
on a Shimadzu 8A (Kyoto, Japan) apparatus equipped with an UV
Shimadzu detector using a PhenomenexC4 column, 22×250 mm
withaflowrateof20 ml min−1, elutedwitha lineargradientof0.1%
TFA in water (A) and 0.1% TFA in CH3CN (B) as described above at
20 ml min−1 flow rate. Mass spectral analysis were carried out on
MALDI-TOFVoyager-DEmass spectrometer Perseptive Biosystems
(Framigham, MA, USA), and LC-MS analyses were performed by
using Finnigan Surveyor MSQ single quadrupole electrospray ion-
ization (Finnigan/ThermoElectronCorporation San Jose, CA, USA).
1H and 13C NMR spectrawere recorded by using 400 spectrometer
Varian (Palo Alto, CA, USA). UV measurements were performed on
a UV-vis Jasco V-5505 spectrophotometer (Easton, MD) equipped
with a Jasco ETC-505T Peltier temperature controller with a 1-cm
quartz cuvette (Hellma).
Peptide Conjugate Synthesis
Peptide synthesis was carried out in solid-phase under standard
conditions using Fmoc strategy on H-Thr(tBu)-ol-(2-chrolotrityl)-
resin (0.70 mmol g−1, 0.15 mmol scale, and 0.214 g). The pep-
tide chain was elongated by sequential coupling and Fmoc
deprotection of the Fmoc-amino acidderivatives: Fmoc-Cys(Acm)-
OH, Fmoc-Thr(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-D-Trp(Boc)-
OH, Fmoc-Phe-OH, Fmoc-Cys(Acm)-OH, and Fmoc-D-Phe-OH. All
couplings were performed twice for 1 h by using an excess of 4
equiv for the single amino acid derivatives. The Fmoc-amino acids
wereactivated in situbythestandardHOBt/PyBop/DIEAprocedure
with DMF as solvent. Fmoc deprotection was carried out by 30%
piperidine in DMF after each coupling step. The coupling steps
were monitored by the qualitative Kaiser test. After completion
of the synthesis of (C18H37)2-CONH(AdOO)5-Octreotide ((C18)2L5-
Oct), the N-terminal Fmoc groupwas removed and five residues of
Fmoc-8-amino-3,6-dioxaoctanoic acid; HOBt, 1-hydroxy-1,2,3-benzotriazole;
ICP, inductively coupled plasma; MRI, magnetic resonance imaging; Oct,
octreotide; PET, positron emission tomography; PyBOP, benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate; SANS, small angle neu-
tron scattering, SPECT, single photon emission computed tomography; SPPS,
solid phase peptide synthesis; SSTR, somatostatin receptor; TFA, trifluoroacetic
acid.
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Fmoc-AdOO-OH were sequentially added. These were coupled to
the N-terminal aminogroupof D-Phe in successive single coupling
step. An excess of 2 equiv of Fmoc-AdOO-OH, PyBop and HOBt,
and 4 equiv of DIEA were dissolved in DMF and added to the
manual vessel. When all five linkers were incorporated into the
peptide chain, the N,N-dioctadecylsuccinamic acid was coupled
using 4 equiv (2.48 g, 4.0 mmol) of the lipophylic compound dis-
solved in 10 ml of DMF/CH2Cl2 (50/50). Then 2.08 g (4.0 mmol) of
PyBop, 0.61 g (4.0 mmol) of HOBt, and 1.34 ml (8.0 mmol) of DIEA,
dissolved in DMF, were addedto the vessel as activating agents.
The coupling timewas 1 hunder aN2 streamat room temperature.
Yield for aliphatic acid coupling, monitored by the Kaiser test, was
in the range 95–98%. The deprotection (Acm removal) and the ox-
idation of the cysteine residues were carried out adding 1.2 equiv
Tl(CF3CO2)3 to a suspension of the peptidyl resin in DMF/anisole
(19 : 1). The reaction mixture was stirred for 18 h at 0 ◦C and the
progress was monitored at intervals by the colorimetric Ellmann
test [29]. The peptide derivatives were cleaved from the solid
support by suspending the resin in 10 ml TFA/TIS/H2O (95.5/2/2.5)
for 120 min. Free peptide derivatives were precipitated in cold
water and lyophilized from a 50%H2O/CH3CN solution. The crude
compounds were purified by preparative RP-HPLC. The single
peaks were analyzed by HPLC and MS. Mass spectral analysis was
carried out on MALDI-TOF. The desired compounds (∼180 mg)
were obtained at HPLC purity higher than 95% and in a final yield
of around 10%.
(C18H37)2-CONH(AdOO)5-Octreotide, (C18)2L5-Octreotide, Rt =
38.0 min; MW = 2328 amu
Synthesis of (C18H37)2CONHLys-(DOTA)CONH2 (C18)2DOTA,
(C18H37)2CONHLys-(DTPA)CONH2 (C18)2DTPA, and
(C18H37)2CONHLys-(DTPAGlu)CONH2 (C18)2DTPAGlu
(C18)2DTPAGlu, (C18)2DTPA, and (C18)2DOTA monomers were
synthesized on solid support under standard conditions using
Fmoc strategy, as reported elsewhere, [25]. The cleavage from
the resin and deprotection of the tBu protecting groups were
performed in 10 ml of TFA/TIS/H2O (95.5/2/2.5) for 120 min. The
crude products were washed several times with small portions
of cold water and lyophilized. The white solids were recrystalized
fromMeOH/H2Oand recovered inhighyield (>85%). Theproducts
were characterized by mass spectra (electrospray ionization ESI)
and NMR spectroscopy.
(C18)2DOTA: MS (ESI+): m/z (%): 1134 (100) [M-H+]
(C18)2DTPA: MS (ESI+): m/z (%): 1123 (100) [M-H+]
(C18)2DTPAGlu: MS (ESI+): m/z (%): 1195 (100) [M-H+]
(C18)2DTPAGlu. 1H-NMR (CDCl3/CD3OD 50/50) (chemical shifts
in δ, CHCl3 as internal standard 7.26) = 4.1 (m, 1H, αCH Lys), 3.5
(overlapped, 1H, αCH Glu), 3.3 (s, 8H, NCH2COOH), 2.7–2.8 (m, 8H,
RNCH2CH2NR), 2.14 (m 2H, C(O)CH2CH2R), 1.87 (m, γ CH2 Lys), 1.76
(m, 2H, δ CH2 Lys), 1.65 (m, 2H, β CH2 Lys), 1.5 (overlapped, 2H,
RCH2CH3), 1.1–1.3 (m, 30 H, 15 CH2), δ 0.8 (t, 3H, 1 CH3).
13C-NMR (CDCl3/CD3OD 50/50) (chemical shifts in δ, CDCl3 as
internal standard 77.00) = 176.2 (5, CO), 172.1 (2, CONH), 163.4
(2, CONH), 55.4 (NHCH(CH2CH2COOH)CO)55.04 (CH2COOH), 54.61
(NH(CH2)4CH), 52.91 (NCH2CH2N), 49.7 (CH3(CH2)16CH2N), 46.4
(CH3(CH2)15CH2CH2N), 38.0 (NHCH2(CH2)2CH2CH), 36.0 (NH
(CH2)3CH2CH), 33.0 (NCOCH2CH2CONH), 32.1 (NHCH(CH2C
H2COOH)CO), 32.0 (NCOCH2CH2CONH), 31.8 (NHCH2CH2
(CH2)2CH), 29.6-26.8 (CH3CH2CH2(CH2)13CH2CH2N), (NHCH(CH2
CH2COOH)CO), 22.57 (CH3CH2CH2(CH2)15), 22.18 (NH(CH2)2CH2
CH2CH), 13.65 (CH3CH2(CH2)16).
(C18)2DTPA. 1H-NMR (CDCl3/CD3OD 50/50) (chemical shifts in
δ, CHCl3 as internal standard 7.26) = 4.3 (m, 1H, CH Lys
α, m, 2H, R2NCH2CONHR), 3.6 (s, 8H, R2NCH2COOH), 3.44
(m, 4H, R2N-CH2CH2N R2), 3.30-3.27 (m, 4H, N-CH2), 3.19 (m,
4H, R2N-CH2CH2NR2), 3.1(m 2H, CH2 Lys ε), 2.6-2.3 (m, 4H,
NHCOCH2CH2CO), 1.90 (m, 2H, CH2 Lys β), 1.6 (m, 2H, CH2 Lys
δ), 1.45 (m, 2H, CH2 Lys γ ), 1.4 (m, 4H, RCH2CH2N), 1.27 (m, 60 CH2
aliphatic), 0.89 (t, 6H, CH3).
13C-NMR (CDCl3/CD3OD 50/50) (chemical shifts in δ, CDCl3
as internal standard 77.00) = 173.31 (4, CO), 172.1 (2, CONH),
163.4 (2, CONH), 55.04 (CH2COOH), 54.51 (NH(CH2)4CH), 52.91
(NCH2CH2N), 49.7 (CH3(CH2)16CH2N), 46.4 (CH3(CH2)15CH2CH2N),
38.0 (NHCH2(CH2)2CH2CH), 36.0 (NH(CH2)3CH2CH), 32.0 (NCOC
H2CH2CONH), 31.8 (NHCH2CH2(CH2)2CH), 29.6-27.0 (CH3CH2
CH2(CH2)13CH2CH2N), 22.57 (CH3CH2CH2(CH2)15), 22.18 (NH
(CH2)2CH2CH2CH), 13.73 (CH3CH2(CH2)16).
(C18)2DOTA. 1H-NMR (CDCl3/CD3OD 50/50) (chemical shifts in δ,
CHCl3 as internal standard 7.26)= 4.1 (m, 1H, CH Lys α), 3.6 (m, 2H,
R2NCH2CONH), 3.1 (m, 6H, R2N-CH2COOH), 3.0 2H, CH2 Lys ε), 3.1
(m, 16 R2N-CH2CH2NR2) 2.4-2.1 (m, 4H, COCH2CH2CO), 1.7 (m, 2H,
CH2 Lys β), 1.4 (m, 2H, CH2 Lys δ), 1.3 (m, 2H, CH2 Lys γ ), 1.1 (m, 4H,
RCH2CH2N), 1.0 (m, 60 CH2 aliphatic), 0.70 (t, 6H, CH3).
13C-NMR (CDCl3/CD3OD 50/50) (chemical shifts in δ, CDCl3
as internal standard 77.00) = 174.0 (3, COOH), 172.8, 172.6,
172.1, 163.0 (4 CONH), 54.5 (CH-Lys α), 53.2 (CH2COOH), 51.50
(NCH2CH2N), 49.7 (CH3(CH2)16CH2N), 46.4 (CH3(CH2)15CH2CH2N),
38.0 (CH2-Lys ε), 36.0 (CH2-Lys β), 32.0 (NCOCH2CH2CONH), 31.8
(CH2-Lys γ ), 29.60-27.0 (CH3CH2CH2(CH2)13CH2CH2N), 22.57
(CH3CH2CH2(CH2)15), 22.2 (CH2-Lys δ), 13.73 (CH3CH2(CH2)16).
Preparation of Gadolinium Complexes
Gadolinium complexes were obtained by adding light excesses of
GdCl3 to the aqueous solutions of ligands at neutral pH and room
temperature. The excess of uncomplexedGd(III) ionswas removed
by centrifugation of the solution brought to pH 10; xylenol orange
test [30] was applied to assure complete removal of Gd(III) ions.
Aggregates Preparation
Self-assembling of (C18)2DOTA, (C18)2DTPA, and (C18)2DTPAGlu
into aggregates and of (C18)2DTPAGlu/(C18)2L5-Oct, (C18)2DTPA/
(C18)2L5-Oct, and (C18)2DOTA/(C18)2L5-Oct (or their correspond-
ing gadolinium complexes) into mixed aggregates was obtained
by dissolving the amphiphiles in small amounts of MeOH/CHCl3
(50/50) mixture and subsequent evaporation of the solvent by
slow rotation of the tube containing the solution under a stream
of nitrogen. In this way, a thin film of amphiphile was obtained.
Then the film was hydrated by the addition of 0.1 M phosphate
buffer, pH 7.4, 0.9% wt NaCl into the vial and sonication for
30 min. All mixed aggregates were prepared at 90/10 molar ratio
of the chelating agent-containing monomer and the octreotide-
containing monomer. The pH was controlled with a pHmeter
MeterLab PHM 220 (Livermore, CA). Concentrations of solutions
weredetermined spectroscopically using amolar extinction coeffi-
cient (ε280) of 5630 M−1 cm−1 for octreotide with its Trp residue in
the sequence [31,32]. In all solutions used for SANS investigations,
wileyonlinelibrary.com/journal/psc Copyright c© 2010 European Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2011; 17: 154–162
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H2O has been replaced by D2O in order to minimize the inco-
herent contribution to the total scattering cross section. The total
concentration in the samples used in structural measurements are
in the 2.0 · 10−3 M range.
Fluorescence Measurements
The fluorescence emission spectra were recorded using a Jasco
Model FP-750 spectrofluorimeter (Easton, MD) equipped with
a Peltier temperature controller in 1.0-cm path length quartz
cell at 25 ◦C. Equal excitation and emission bandwidths were
used throughout the experiments, with a recording speed of
125 nmmin−1 and automatic selection of the time constant. Trp
emission spectra in 290–450 nm range were obtained exciting
at 280 nm the micelle solutions at a peptide concentration of
1.0 · 10−5 M.
Small-Angle Neutron Scattering (SANS)
SANS were performed at 25 ◦C with the KWS2 and V4 instruments
located at the Heinz Meier Leibtnitz Source, (Garching, Germany)
and at the Helmholtz Zentrum (Berlin, Germany), respectively,
with a setup widely described elsewhere [25,33]. The investigated
systems were contained in a closed quartz cell, in order to prevent
solvent evaporation and were kept under measurements for the
period required for ∼2 million counts. The obtained raw data
were then corrected for background and empty cell scattering.
Detector efficiency corrections, radial average, and transformation
to absolute scattering cross sections d/d were made with
plexiglass or water as secondary standards [34].
Water Proton Relaxation Measurements
The proton 1/T1 NMRD profiles were measured over a continuum
of magnetic field strength from 0.00024 to 0.47 T (corresponding
to 0.01–20 MHz proton Larmor Frequency) on a Stelar Fast Field-
Cycling relaxometer (Mede Pavia, Italy). This relaxometer works
under complete computer control with an absolute uncertainty in
1/T1 of ±1%. Data points from 0.47 T (20 MHz) to 1.7 T (70 MHz)
were added to the experimental NMRDprofiles andwere recorded
on the Stelar Spinmaster spectrometer (Mede Pavia, Italy) with
switchable field from 20 to 70 MHz, by means of the standard
inversion-recovery technique (16 experiments, 2 scans). A typical
90◦ pulsewidthwas 4 µs and the reproducibility of the T1 datawas
±0.5%. The temperature was kept at 25 ◦C with a Stelar VTC-91
airflowheater (MedePavia, Italy) equippedwith a copper-constant
thermocouple (uncertainty ±0.1 ◦C), respectively. Relaxivity data
at 20 MHz were measured on both instruments.
17O-NMR Water Relaxation Rate Measurements
The exchange lifetime of a metal-bound water molecule in a
paramagnetic chelate may be accurately assessed by measuring
the temperature dependence of the paramagnetic contribution
to the water 17O transverse relaxation rate (Ro2p). Variable
temperature 17ONMRmeasurementswere recordedon theBruker
EX-600 spectrometer (Bruker Biospin, Rheinstetten, Germany)
equipped with a 5-mm probe, by using a D2O external lock.
Experimental settings were spectral width 10 000 Hz, 90◦ pulse
(7 µs), acquisition time 10 ms, 1000 scans, andno sample spinning.
Solutions containing 2.6% of 17O isotope (Yeda, Israel) were
used. The paramagnetic contribution to the transverse relaxation
rates (Ro2p) were calculated from the signal width at half-height
[ν1/2 corrected for the diamagnetic contribution (ν1/2dia) :
Ro2p = π (ν1/2−ν1/2dia)]. The temperature dependences of the
diamagnetic contribution to the observed transverse relaxation
rates were measured by using 17O isotope-enriched pure water.
Results and Discussion
Monomers Design and Synthesis
The schematic representation of the synthetic monomers, both
containingahydrophobicandahydrophilicmoiety,usedto formu-
late mixed aggregates is reported in Figure 1. The first monomer
(C18H37)2NCO(CH2)2CO(AdOO)5-Oct ((C18)2L5-Oct) contains two
C18 hydrophobic moieties bound to the N-terminus of the
cyclic peptide octreotide, and spaced from the bioactive peptide
by five units of dioxoethylene linkers. The second monomer
(C18)2DTPAGlu, (C18)2DTPA, or (C18)2DOTA, contains two C18
hydrophobicmoieties bound, througha lysine residue, todifferent
polyamino-polycarboxy ligands: DTPAGlu, DTPA, or DOTA. DTPA
or its glutamic analog DPTAGlu belong to the branched class
of chelating agents, while DOTA belongs to the macrocycle
chelating agents. The gadolinium ion can be complexed by nine
ligands. The three chelating agents provide a set of eight donor
couples of electrons, thus leaving the ninth position free for water
coordination and allowing water exchange in the gadolinium
coordination sphere. They were selected to study the influence of
the steric hindrance and of the residual charge in the hydrophilic
shell on the aggregation behavior. In fact, the expected difference
betweenthethreechelatingagentsandtherespectiveamphiphilic
monomers, are essentially due to the number of charges. They
have 5, 4, and 3 negative charges as free bases and 2, 1, and 0 as
gadolinium complexes, respectively.
In the peptide monomer, in order to maintain an appropri-
ate exposition of the peptide on the external aggregate surface,
five units of 8-amino-3,6-dioxaoctanoic acid (AdOO) were intro-
duced between the hydrophobic double-tails and the octreotide
N-terminal residue. The AdOO linker was chosen both to increase
the hydrophilicity of the head without changing the charge of
the monomers and to reduce aggregate clearance through the
reticulo-endothelial system (RES) [35]. Moreover, the number of
linkers was selected according to biological results previously ob-
tained with similar aggregates prepared from derivatized CCK8
[22] or 7-14-bombesin [25], in order to favor a good exposure of
octreotide on the external aggregate surface. It is already known
that chemical modification of the residue of the octreotide at the
N-terminal D-Phe by hydrophilic or hydrophobic chain does not
modify the peptide affinity toward the receptors [36].
In both monomers, two alkyl chains of 18 carbon atoms were
chosen as hydrophobic moieties in order to obtain a structure
similar to the membrane phospholipidic bilayer, thus avoiding
hemolytic effects on the cells [37]. Moreover, the 18th carbon
chains provide a sufficient number of Van der Waals interactions
to obtain stable aggregates.
Amphiphilic monomers were synthesized by solid-phase meth-
ods according to standard SPPS protocols [38]. Two different
polymeric supports were used for the synthesis: Rink AmideMBHA
resin for the chelating agent monomers; preloaded 2-chloro-trityl
resin for thepeptidemonomer. PreloadedH-Thr(tBu)-ol-(2-chloro-
trityl) polymeric resin allows to obtain the alcoholic function on
the octreotide C-terminus. At the end of the monomer assembly,
the acetamidomethyl protecting groups were removed from the
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Figure 1. Schematic representation of amphiphilic monomers: (A) (C18H37)2N-CO(CH2)2CO-(AdOO)5-Octreotide [(C18)2L5-Oct]; (B) (C18H37)2N-
CO(CH2)2CO-Lys(DTPAGlu-Gd)-NH2 [(C18)2DTPAGlu(Gd)]; (C) (C18H37)2N-CO(CH2)2CO-Lys(DTPA-Gd)-NH2 [(C18)2DTPA(Gd)]; (D) (C18H37)2N-CO(CH2)2CO-
Lys(DOTA-Gd)-NH2 (C18)2DOTA(Gd). The amino acid sequence of octreotide is reported by using the three-letter code.
cysteine residues and disulfide bridge formation was achieved by
Tl(CF3CO2)3 treatment on the solid support. Monomer cleavages
were performed using standard trifluoroacetic acid mixtures to
allow for complete removal of all protecting groups of the amino
acid side chains and of the tert-butyl groups from the carboxylic
functionsof thechelatingagents.Thecrudeproductswerepurified
by preparative reversed-phase HPLC or recrystallization to a final
purity of 90% and were isolated in 30–40% yields in lyophilized
form. Their molecular masses were determined by MALDI-TOF
mass spectroscopy.
(C18)2DTPAGlu(Gd), (C18)2DTPA(Gd), and (C18)2DOTA(Gd)
gadolinium complexes were obtained by adding increasing
amounts of a concentrated GdCl3 solution to the free base
monomers at neutral pH and at room temperature. To avoid the
relaxivity contribution of free gadolinium, the excess metal ions
were removed at pH 10 as insoluble hydroxide as already reported
for other DTPA or DOTA like gadolinium complexes. The Gd(III)
titration isconveniently followedbymeasuring1H-relaxationrates.
Self-assemblingaggregates containingonly the chelatingagent
monomers and mixed aggregates at 90/10 molar ratio between
chelating agent monomer and peptide monomer were prepared
by well-assessed sonication and extrusion procedures in 0.1 M
phosphate buffer at pH 7.4 and physiological ionic conditions
(0.9% wt). Larger amounts of peptide in the final composition of
mixed aggregates were avoided in order to circumvent inter-
chain peptide interaction and to preserve the right peptide
conformation for the receptor binding. Peptide concentration
in mixed aggregates was determined by UV spectroscopy. The
exposure of the bioactive octreotide portion of the monomers
on the surface of the aggregates was evaluated by monitoring
the fluorescence of the of the tryptophan residue. Usually, this
fluorophore shows an emission peak centered at 350 nm in
polar solvents while in hydrophobic solvents the maximum is
blue-shifted to 330 nm [39]. The fluorescence emission spectra
of all aggregates (Figure 2) recorded at 25 ◦C and at a peptide
concentration of 1.0× 10−5 M show amaximum at∼340 nm. This
is typical of a Trp of class II (about 340 nm) corresponding to the
emission of this fluorophores contacting water molecules of low
mobility at the protein surface [39].
Small-Angle Neutron Scattering
SANS measurements were performed on (C18)2DTPAGlu/(C18)2
L5-Oct/D2O, (C18)2DTPA/(C18)2L5-Oct/D2O, and (C18)2DOTA/
(C18)2L5-Oct/D2O ternary systems, in which chelating agents
are present as free bases or as gadolinium complexes. The
wileyonlinelibrary.com/journal/psc Copyright c© 2010 European Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2011; 17: 154–162
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Figure 2. Fluorescence spectrum of tryptophan residue in
(C18)2DTPAGlu(Gd)/(C18)2L5-Oct (), (C18)2DTPA(Gd)/(C18)2L5-Oct
(◦), and (C18)2DOTA(Gd)/(C18)2L5-Oct (•) mixed aggregates. Peptide
concentration in the samples was 1.0 · 10−5 M. The spectrum was excited
at 280 nm.
corresponding binary systems (C18)2DTPAGlu-D2O, (C18)2DTPA-
D2O, and (C18)2DOTA-D2Ohavebeenalso studied for comparison.
The scattering profile of a sample containing only (C18)2L5-Oct is
quite flat, indicating that at this concentration solute aggregates
are absent or in negligible amounts (data not shown).
Figure 3(A) and 3(B) shows the scattering cross section trend,
d
∑
/d versus q, of the ternary and binary systems, respectively.
Figure 3(A) shows that (C18)2DTPAGlu/(C18)2L5-Oct/D2O and
(C18)2DTPAGlu(Gd)/(C18)2L5-Oct/D2O ternary systems show the
typical form factor of small aggregates, i.e. spherical or ellipsoidal
micelles. Indeed for the system containing Gd, a very small region
in which a power law d
/
d ∝ q−2, typical of two-dimensional
objects, is present. Actually, as the Guinier region of liposomes
and vesicles belongs to the USANS q range, these aggregates
are seen, in the SANS domain as a collection of bilayers giving
rise to the power law found. On the other hand, ternary systems
based on DOTA chelating agents, as free base or as gadolinium
complex, have scattering cross sections d/d, scaling as q−2
typical of vesicles and liposomes,without any detectable presence
of smaller aggregates. Finally, the ternary systems based on DTPA
or DTPA (Gd) show the presence of a power law d
/
d ∝ q−1
and d
/
d ∝ q−2, respectively, indicating the presence of uni-
dimensional objects like cylindrical micelles and the presence of
vesicles, respectively.
Structural differences between the aggregates formulated by
starting from the three chelating agents can be rationalized on
the basis of their different number of carboxylic groups that at
pH 7.4 are completely deprotonated. In fact, the negative charges
diminish going from −5 for DTPAGlu to −4 for DTPA and −3 for
DOTA.After theirgadoliniumcomplexation,−2,−1and0negative
charges remain for each DTPAGlu, DTPA, and DOTA, respectively.
According to our previous findings, a reduction of the negative
charges on these kinds of aggregates should promote a total or a
partialmicelle-to-vesicle transition.Adecreaseofnegative charges
in the surfactant head-group allows a decrease of the electrostatic
repulsion between the head-groups, thus favoring the formation
of large and low curvature aggregates such as bilayer structures
or liposomes.
The ternary systems do not differ significantly from the
respective binary systems (Figure 3(B)) except for the coexistence
of micelles and vesicles for the systems containing the DTPAGlu
molecule. The low difference can be ascribed to the relative
low amount of the (C18)2L5-Oct in mixed aggregates (10%) that
probably does not influence in significant way the size and shape
of the self-assembling aggregates.
Appropriate SANSmodels have been fitted to the experimental
data by applying the appropriate form factor in dependence of the
system analyzed, provided the solutions are quite dilute and inter-
particle interactions are negligible. Systems containing two kinds
of aggregates have been treated assuming each kind of aggregate
scattered independently from the other and expressing the cross
section as the sum of the form factors weighted for two scale
factors depending on the relative density number of the objects
and treating them as adjustable parameters.
Table 1 shows that the thicknesses of the bilayers are substan-
tially constant, around 50 Å, in the analyzed systems.
Relaxivity Measurements
The key parameter for the evaluation of the efficiency of an
MRI contrast agent is its relaxivity, i.e. the power to shorten the
relaxation times of the solvent water protons. The measured
relaxivity value (r1 p) is defined as the paramagnetic contribution
to the measured proton longitudinal relaxation rate (R1 obs) of a
solution containing 1.0 mM concentration of gadolinium complex
according to Eqn (1) [40]
R1 obs = [GdL]r1 p + R1 W (1)
whereR1 w is thediamagneticcontributionofpurewater (0.38 s−1).
The relaxivity values determined (at 20 MHz and 25 ◦C) for the
ternary systems are reported in Table 2. Moreover, relaxivity was
measured as a function of the appliedmagnetic field to obtain the
so-called NMRD (nuclear magnetic resonance dispersion) profiles
reported in Figure 4. The Gd(III) concentration of all the measured
samples was obtained by mineralization with HCl 37% at 120 ◦C
overnight: fromthemeasureof theobservedrelaxation rate (R1 obs)
of the acidic solution, knowing the relaxivity (r1 p) of Gd(III) ion in
acidic conditions (13.5 mM−1 s−1), it was possible to calculate the
exact Gd(III) concentration (Eqn (1)) (this method was calibrated
using standard inductively coupledplasma (ICP) solutions, and the
accuracy was determined to be 1%). At this point, knowing [GdL]
and measuring R1 obs of the micellar mother solution, the same
Eqn (1) was used to calculate the micelle relaxivity.
NMRDprofilesweremeasuredon (C18)2DTPAGlu(Gd)/(C18)2L5-
Oct/H2O, (C18)2DTPA(Gd)/(C18)2L5-Oct/H2O, and (C18)2DOTA
(Gd)/(C18)2L5-Oct/H2O ternary systems. The analysis of NMRD
profiles of the lipophilic aggregated systems has been made ac-
cording to the Solomon–Bloembergen–Morganmodel, modified
according to the Lipari–Szabo approach [41–43] to obtain an
accurate determination of the reorientational correlation time (τR)
that is strictly related to the molecular size of the investigated
system. This model is generally applied to the systems with a
faster local motion (governed by τl) and a slower global motion
(governed by τg); the extent of local to global contribution to the
overall motion is determined by an order parameter (S2) that can
vary from 0 to 1. The experimental data reported in Figure 4 were
fittedby considering onewatermolecule in the inner coordination
sphere for each Gd(III) complex (nw = 1) and a Gd-H distance of
3.1 Å.
Concerning reorientational correlation times (τg and τl), the
global correlation times are quite similar in the case of the
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Figure 3. Scattering intensity profile for the following mixed systems at pH 7.4:
The solid line represents the fitting curve to the experimental data through the model reported in the text. For a better comparison, cross sections have
been multiplied for a scale factor.
Table 1. Liposomal bilayer thickness (d) obtained for the systems
investigated by means of SANS. The table also reports the radius of
cylindrical micelles and the radius of spherical micelles, where found
Aqueous system d/(´Å) Rcyl/(´Å) Rsph/(´Å)
(C18)2DOTA(Gd)/D2O 45 ± 4 – –
(C18)2DOTA/D2O 41 ± 2 – –
(C18)2DTPA(Gd)/D2O 50 ± 5 – –
(C18)2DTPA/D2O – 33 ± 3 –
(C18)2DTPAGlu(Gd)/D2O 72 ± 9 – –
(C18)2DTPAGlu/D2O 53 ± 8 – –
(C18)2DOTA(Gd)/(C18)2L5-Oct/D2O 53 ± 2 – –
(C18)2DTPA(Gd)/(C18)2L5-Oct/D2O 51 ± 3 – –
(C18)2DTPAGlu(Gd)/(C18)2L5-Oct/D2O 49 ± 3 – 21 ± 2
(C18)2DTPAGlu/(C18)2L5-Oct/D2O – – 20 ± 2
(C18)2DTPA/(C18)2L5-Oct/D2O – 28 ± 7 –
(C18)2DOTA/(C18)2L5-Oct/D2O 50 ± 3 –
micellar ternary systems containing (C18)2DTPAGlu(Gd) and
(C18)2DTPA(Gd), while a consistently higher τg value has been
found in the case of the bigger vescicular system containing
(C18)2DOTA(Gd). Quite surprisingly, a drop in the local correlation
time (τl) going from (C18)2DTPAGlu(Gd) to (C18)2DTPA(Gd) and
(C18)2DOTA(Gd) containing systems has been found. For the
(C18)2DTPAGlu(Gd)/(C18)2L5-Oct/H2O mixed aggregate a set of
parameters very close to the one of the corresponding to the
ternary aggregate with CCK8 peptide [22] was observed.
Oneof thekeyparametersgoverningtherelaxivityofaGd-based
contrast agent is the exchange lifetimeof thewatermolecule coor-
dinated to the metal ion (τM); this parameter is usually best
determined by measuring the temperature dependence of the
transverse relaxation rate of the 17O water resonance. The ex-
change lifetime of (C18)2DTPAGlu(Gd) has been previously
determined and reported [22]. On the other hand, the direct
17O-NMR R2p versus T measurements were performed in the
case of (C18)2DTPA(Gd) (Table 2), while the low solubility of the
(C18)2DOTA(Gd) system prevented any direct 17O-NMR measure
and the τM value was left free to fit during the NMRD quantitative
analysis. As expected on the basis of previously reported results
[44,45], the water exchange lifetimes of the mono amides such as
(C18)2DTPA(Gd) and (C18)2DOTA(Gd) are consistently slower than
the one relative to (C18)2DTPAGlu(Gd). From inspection of the
Table 2, a decreasing trend in relaxivity valueswas observed going
from (C18)2DTPAGlu(Gd) to (C18)2DTPA(Gd) to (C18)2DOTA(Gd)
containing ternary systems.
This phenomena can be well explained by a comparative
analysis of relaxometric parameters. It is strictly related to
the increase in the corresponding coordinated water exchange
lifetimes (τM) which, for high molecular weight slowly moving
systems, is known to be a limiting factor for values higher than
30–50 ns.
Conclusions
Supramolecular aggregates containing a high number of para-
magnetic gadolinium complexes on their hydrophilic shell have
been developed. They present high relaxivity values typical of the
new generation of MRI contrast agents, based on nanoparticles
obtained by lipophilic Gd(III) complexes. [46,47]. The presence of
a small amount of amphiphilic octreotide monomer exposed on
the aggregate surface gives the entire nanoparticles a potential
binding selectivity toward somatostatin sstr2 receptor subtype.
Structural differences between the aggregates formulated by
starting from the three chelating agents, or from their gadolinium
complexes, have been observed and rationalized on the basis of
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Table 2. Principal relaxometric parameters measured at pH 7.4, T = 298 K as derived from the fitting of NMRD (τR, 2, τV) and 17O-NMR (τM) data
Systems r1 p (mM−1 s−1) τl (ps) τg (ps) S τM (ns) τv (ps) 2 (×1019 s−2)
(C18)2DTPAGlu(Gd)/(C18)2L5-Oct 17.6 302 2546 0.41 81 49.2 1.18
(C18)2DTPA(Gd)/(C18)2L5-Oct 15.2 63.5 2111 0.49 205 56.2 0.83
(C18)2DOTA(Gd)/(C18)2L5-Oct 10.0 65.5 3434 0.34 750 47.5 0.79
For fitting of NMRD profiles, Gd-H distance of the inner sphere water molecule was fixed to 3.1 Å, the distance of closest approach of outer sphere
water molecules was fixed to 3.8 Å and the diffusion coefficient of the water molecules was fixed to 2.24 × 10−5 cm2 s−1.
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Figure 4. 1/T1 profiles of NMRD of (C18)2DTPAGlu(Gd)/(C18)2L5-Oct (),
(C18)2DTPA(Gd)/(C18)2L5-Oct (), and (C18)2DOTA(Gd)/(C18)2L5-Oct (•)
at pH 7.4 and 298 K, normalized to 1 mM concentration of Gd(III) ion, as
function of frequency (MHz). The solid curves through the data pointswere
calculated with the parameters reported in Table 2. Relaxivity parameters,
reported in Table 2, are measured at 20 MHz.
their different residual charge. According to other reported sys-
tems [39], a decrease of the negative charges on the aggregate
surface diminishes the electrostatic repulsion between the head-
groups, thus favoring the formation of large and low curvature
aggregates such as bilayer structures or liposomes. This finding
promotes a micelle-to-vesicle transition going from −2 for DT-
PAGlu(Gd) to −1 for DTPA(Gd) and 0 for DOTA(Gd). A decrease
in relaxivity values (from r1 p = 17.6 to 10.0 mM−1 s−1), due to
an increase of water exchange lifetimes (τM) of the mono amides,
was observed going from (C18)2DTPAGlu(Gd) to (C18)2DOTA(Gd)
containing ternary systems.
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